Munich Leukemia Laboratory (MLL) has entered into a research collaboration with IBM Watson and Illumina to enhance diagnostics and develop personalised treatment tools for leukemia and lymphoma.

The new cognitive technology prototype will focus on aiding researchers in leukemia treatment.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Illumina will provide its NovaSeq technology to MLL, which plans to use the technology to sequence samples from its biobank of more than 500,000 cases.

Watson will then help MLL to interpret the genomic data and other data sources.

The testing processes such as automated phenotyping and genotyping including whole genome sequencing (WGS) and transcriptome sequencing (RNA-Seq) in 5,000 cases will also be included in the project.

The primary focus of the collaboration is to develop a Watson-based technology prototype that can analyse genomic and phenotypic data, in parallel to, medical literature, guidelines and study results, to provide information relevant to leukemia care.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

MLL co-founder and chief executive officer Torsten Haferlach said: “We at MLL are excited to combine our data and knowledge, IBM’s cognitive computing tools, and Illumina’s new sequencing platform to create a new era of insights in leukemia biology that will also drive more personalised treatment strategies.”

"MLL intends to use Illumina’s BaseSpace Informatics suite to streamline data analysis, storage, data curation and aggregation."

MLL intends to use Illumina’s BaseSpace Informatics suite to streamline data analysis, storage, data curation and aggregation.

It is expected that the BaseSpace Sequence Hub Frankfurt site will assist MLL in managing the data as the project scales and facilitates data transfer to IBM Watson.

MLL plans to further combine its genomic data with other clinical data, following additional tertiary analysis using BaseSpace Cohort Analyzer and BaseSpace Correlation Engine.


Image: Illumina's NovaSeq device. Photo: courtesy of Illumina, Inc.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact